Home
How It Works
Solutions
Resources
Events
Blog
Case Studies
For Academic Experts
Sign Up
Login

Work with thought leaders and academic experts in Oncology

Companies can greatly benefit from working with an expert in the field of Oncology. Here are a few reasons why: 1. Cutting-edge Research: Oncology experts stay updated with the latest advancements in cancer research, providing valuable insights and innovative solutions. 2. Clinical Trials: Collaborating with an Oncology researcher allows companies to conduct clinical trials, accelerating the development of new treatments and therapies. 3. Expertise in Precision Medicine: Oncology researchers specialize in personalized medicine, helping companies develop targeted therapies based on individual patient characteristics. 4. Access to Networks: Academic researchers in Oncology have extensive networks within the medical community, providing access to key opinion leaders, clinicians, and other experts. 5. Regulatory Compliance: Oncology experts are well-versed in regulatory requirements, ensuring companies meet all necessary guidelines and standards.

Researchers on NotedSource with backgrounds in Oncology include Ramy Ayoub, Luca Delfinis, Gwendolyn Thomas, Ph.D., CSCS, USAW-L1, Dr. Everson A Nunes, Ph.D., Dr. Shilpa Patil, Ph.D, Boris Leibovitch, Dr. Michael W. Craige, PhD, MBA, and Dushani L. Palliyaguru, Ph.D..

Ramy Ayoub

Toronto, Ontario, Canada
PhD Medical Biophysics
Most Relevant Research Expertise
Oncology
Other Research Expertise (10)
neuro-oncology
mouse imaging
cancer therapy
normal tissue toxicity
Radiology, Nuclear Medicine and imaging
And 5 more
About
Ramy Ayoub obtained his Ph.D. in Medical Biophysics from the University of Toronto in 2023, where he developed a strong foundation in the principles and applications in neuroscience, statistics, machine learning, imaging & radiation physics. During his time at the University of Toronto, Ramy has been involved in conducting cutting-edge research in the field, with a focus on developing new technologies and pharmacological interventions to improve healthcare outcomes. He is passionate about using his skills and expertise to make a positive impact in the medical field and is dedicated to advancing the field through his ongoing research and contributions.
Most Relevant Publications (2+)

7 total publications

QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY

Neuro-Oncology / Jun 01, 2018

Ayoub, R., Miller, F., Beera, K., de Medeiros, C., Laughlin, S., Bouffet, E., & Mabbott, D. (2018). QOL-53. METFORMIN RESULTS IN HIPPOCAMPAL REMODELING AND IMPROVED MEMORY ENCODING IN PAEDIATRIC BRAIN TUMOR SURVIVORS TREATED WITH CRANIAL RADIATION: A PILOT RANDOMIZED CONTROLLED CROSSOVER STUDY. Neuro-Oncology, 20(suppl_2), i168–i168. https://doi.org/10.1093/neuonc/noy059.634

MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma

Neuro-Oncology / Jun 01, 2022

Smith, K., Bihannic, L., Gudenas, B., Gao, Q., Haldipur, P., Tao, R., Iskusnykh, I., Chizhikov, V., Scoggins, M., Zhang, S., Edwards, A., Deng, M., Glass, I., Overman, L., Millman, J., Sjoboen, A., Hadley, J., Mankad, K., Onar-Thomas, A., … Northcott, P. (2022). MEDB-78. Unified rhombic lip origins of Group 3 and Group 4 medulloblastoma. Neuro-Oncology, 24(Supplement_1), i124–i125. https://doi.org/10.1093/neuonc/noac079.452

See Full Profile

Luca Delfinis

Toronto, Ontario, Canada
PhD candidate in physiology researching the mechanisms that drive muscle dysfunction in cancer
Research Expertise (3)
Physiology
Physiology (medical)
Cell Biology
About
Luca Delfinis is a PhD candidate at York University where his research focuses on muscle dysfunction in cancer. Luca has been a part of several research collaborations both nationally and internationally throughout his PhD that has helped him gain unique perspectives in physiology, especially in the context of metabolism. He has also presented at several conferences where he has discussed data with leaders in cachexia, metabolism, exercise and more.

See Full Profile

Gwendolyn Thomas, Ph.D., CSCS, USAW-L1

Philadelphia, Pennsylvania, United States of America
Resistance Exercise Physiologist/Performance Enhancement/Optimizing RE Prescription
Most Relevant Research Expertise
Oncology
Other Research Expertise (30)
resistance exercise
obesity
breast cancer
chronic disease
inflammation
And 25 more
About
My work has focused on how we can use data to support decisions to individualize monitoring to optimize human performance.  My work has demonstrated that a one size fits all approach is not the way to optimize performance in any setting.  My monitoring approach is one that utilizes a network physiology paradigm, which focuses on nonlinear dynamic interactions. In my athlete monitoring I focus on leveraging EMA and wearables; biological sampling and resistance exercise and conditioning prescribed to elicit a specific biological response.    Additionally, as a practitioner it is important to understand the limitations of athlete monitoring, which is another area research and practice has focused.  This is an important skillset that is currently being utilized by the in a project entitled “Integrating mHealth and Physical Function to Develop a Predictors of Injury and Optimal Performance Model in Special Military Operators “with the Rangers in the 3/75 Ranger Battalion.  This approach is one that quantifies factors such as dosage variables of training and lifestyle factors (sleep, nutrition, life stress).  Using this data, we are working on individualizing acute training sessions to optimize readiness and performance enhancement.   During my time at Syracuse University, I was the professor of record to teach the NSCA CSCS preparation course and lead the strength and conditioning program.  We were developing a master’s in exercise science and I was in the process of working on certification with the NSCA.  We also worked closely with athletics to secure strength and conditioning assistantships to allow for student funding.  I am currently on several NSCA committees, which include the Education and Women’s Committee (next certification cycle).    I am particularly adept at all phases of the athletic performance enhancement and these experiences have given me expertise in evidence based program design, linear and non-linear periodization, exercise endocrinology, resistance exercise physiology and acute and chronic training readiness and non-training parameters
Most Relevant Publications (9+)

51 total publications

Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation

BMC Cancer / Jan 22, 2019

van Rooijen, S., Carli, F., Dalton, S., Thomas, G., Bojesen, R., Le Guen, M., Barizien, N., Awasthi, R., Minnella, E., Beijer, S., Martínez-Palli, G., van Lieshout, R., Gögenur, I., Feo, C., Johansen, C., Scheede-Bergdahl, C., Roumen, R., Schep, G., & Slooter, G. (2019). Multimodal prehabilitation in colorectal cancer patients to improve functional capacity and reduce postoperative complications: the first international randomized controlled trial for multimodal prehabilitation. BMC Cancer, 19(1). https://doi.org/10.1186/s12885-018-5232-6

Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study

Cancer Prevention Research / Feb 01, 2013

Jones, S. B., Thomas, G. A., Hesselsweet, S. D., Alvarez-Reeves, M., Yu, H., & Irwin, M. L. (2013). Effect of Exercise on Markers of Inflammation in Breast Cancer Survivors: The Yale Exercise and Survivorship Study. Cancer Prevention Research, 6(2), 109–118. https://doi.org/10.1158/1940-6207.capr-12-0278

Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review

Current Breast Cancer Reports / May 17, 2013

Playdon, M., Thomas, G., Sanft, T., Harrigan, M., Ligibel, J., & Irwin, M. (2013). Weight Loss Intervention for Breast Cancer Survivors: A Systematic Review. Current Breast Cancer Reports, 5(3), 222–246. https://doi.org/10.1007/s12609-013-0113-0

What you should know about the low anterior resection syndrome – Clinical recommendations from a patient perspective

European Journal of Surgical Oncology / Sep 01, 2018

van der Heijden, J. A. G., Thomas, G., Caers, F., van Dijk, W. A., Slooter, G. D., & Maaskant-Braat, A. J. G. (2018). What you should know about the low anterior resection syndrome – Clinical recommendations from a patient perspective. European Journal of Surgical Oncology, 44(9), 1331–1337. https://doi.org/10.1016/j.ejso.2018.05.010

Awareness and management of low anterior resection syndrome: A Dutch national survey among colorectal surgeons and specialized nurses

European Journal of Surgical Oncology / Feb 01, 2019

Thomas, G., van Heinsbergen, M., van der Heijden, J., Slooter, G., Konsten, J., & Maaskant, S. (2019). Awareness and management of low anterior resection syndrome: A Dutch national survey among colorectal surgeons and specialized nurses. European Journal of Surgical Oncology, 45(2), 174–179. https://doi.org/10.1016/j.ejso.2018.11.001

What you should know about the low anterior resection syndrome – clinical recommendations from a patient perspective

European Journal of Surgical Oncology / Feb 01, 2019

Van Der Heijden, J., Thomas, G., Caers, F., van Dijk, W., Slooter, G., & Maaskant-Braat, S. (2019). What you should know about the low anterior resection syndrome – clinical recommendations from a patient perspective. European Journal of Surgical Oncology, 45(2), e54. https://doi.org/10.1016/j.ejso.2018.10.210

Trends in Diet and Cancer Research: A Bibliometric and Visualization Analysis

Cancers / Jul 25, 2023

Giles, E. D., Purcell, S. A., Olson, J., Vrieling, A., Hirko, K. A., Woodruff, K., Playdon, M. C., Thomas, G. A., Gilmore, L. A., Moberly, H. K., & Newell-Fugate, A. E. (2023). Trends in Diet and Cancer Research: A Bibliometric and Visualization Analysis. Cancers, 15(15), 3761. https://doi.org/10.3390/cancers15153761

Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities

JNCI Monographs / May 04, 2023

Gilmore, L. A., Parry, T. L., Thomas, G. A., & Khamoui, A. V. (2023). Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities. JNCI Monographs, 2023(61), 30–42. https://doi.org/10.1093/jncimonographs/lgad006

Implementation and evaluation of a screening and treatment protocol for the low anterior resection syndrome

European Journal of Surgical Oncology / Feb 01, 2019

Van Der Heijden, J., van Heinsbergen, M., Thomas, G., Caers, F., Slooter, G., & Maaskant-Braat, S. (2019). Implementation and evaluation of a screening and treatment protocol for the low anterior resection syndrome. European Journal of Surgical Oncology, 45(2), e43. https://doi.org/10.1016/j.ejso.2018.10.178

See Full Profile

Dr. Everson A Nunes, Ph.D.

Hamilton, Ontario, Canada
Post-Doctoral Fellow at McMaster University | former Associate Professor - Physiological Sciences
Most Relevant Research Expertise
Oncology
Other Research Expertise (39)
skeletal muscle
nutrition
physical activity
obesity
cancer
And 34 more
About
Dr. Everson A Nunes is a highly accomplished researcher and educator in the field of physiological sciences. He received his Ph.D. in Cellular and Molecular Biology with a focus on Physiological Sciences from Universidade Federal do Paraná in 2009, after completing a BSc in Human Nutrition and an MSc in Physiological Sciences. He also holds a specialization in Exercise Physiology and a BSc in Biological Sciences from Universidade Federal do Paraná. Dr. Nunes has a strong background in research, having completed two post-doctoral fellowships at McMaster University and Universidade Federal do Paraná. He has also held positions as an associate professor and assistant professor at Universidade Federal de Santa Catarina. He has published numerous articles in peer-reviewed journals, and his research focuses on the effects of exercise and nutrition on physiological processes in the human body. In addition to his research, Dr. Nunes is also a dedicated educator. He has taught at various universities in Brazil, including Universidade Federal de Santa Catarina, Universidade Gama Filho, Faculdades Integradas Espírita, Pontificia Universidade Católica do Paraná, and Faculdade do Litoral Sul. He is known for his dynamic teaching style and his ability to engage students in complex physiological concepts. Dr. Nunes is a member of several professional organizations, including the American Society for Nutrition, the Canadian Society of Exercise Physiology, the Canadian Nutrition Society and the Brazilian Society of Physiology. He is also a regular speaker at national and international conferences, sharing his expertise and research findings with colleagues and students. Overall, Dr. Nunes is a highly qualified and experienced professional in physiological sciences, metabolism, cancer and nutrition. His dedication to research and education makes him a valuable asset to any institution.
Most Relevant Publications (6+)

97 total publications

Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats?

Nutrition and Cancer / Sep 21, 2016

Schiessel, D. L., Yamazaki, R. K., Kryczyk, M., Coelho de Castro, I., Yamaguchi, A. A., Pequito, D. C. T., Brito, G. A. P., Borghetti, G., Aikawa, J., Nunes, E. A., Naliwaiko, K., & Fernandes, L. C. (2016). Does Oil Rich in Alpha-Linolenic Fatty Acid Cause the Same Immune Modulation as Fish Oil in Walker 256 Tumor-Bearing Rats? Nutrition and Cancer, 68(8), 1369–1380. https://doi.org/10.1080/01635581.2016.1224364

Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer

Nutrition and Cancer / Dec 23, 2015

Camargo, C. de Q., Mocellin, M. C., Pastore Silva, J. de A., Fabre, M. E. de S., Nunes, E. A., & Trindade, E. B. S. de M. (2015). Fish oil supplementation during chemotherapy increases posterior time to tumor progression in colorectal cancer. Nutrition and Cancer, 68(1), 70–76. https://doi.org/10.1080/01635581.2016.1115097

Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status

Nutrition and Cancer / Feb 24, 2015

Camargo, C. de Q., Borges, D. da S., Oliveira, P. F. de, Chagas, T. R., Del Moral, J. A. G., Durigon, G. S., Dias, B. V., Vieira, A. G., Gaspareto, P., Trindade, E. B. S. de M., & Nunes, E. A. (2015). Individuals with Hematological Malignancies Before Undergoing Chemotherapy Present Oxidative Stress Parameters and Acute Phase Proteins Correlated with Nutritional Status. Nutrition and Cancer, 67(3), 463–471. https://doi.org/10.1080/01635581.2015.1004732

Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats

Journal of Cancer Science & Therapy / Jan 01, 2014

Bordignon, J. (2014). Exercise and Shark Liver Oil Supplementation Reduce Tumor Growth and Cancer Cachexia in Walker 256 Tumor Bearing Rats. Journal of Cancer Science & Therapy, 06(03). https://doi.org/10.4172/1948-5956.1000254

Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats

Nutrition and Cancer / Feb 01, 2012

Kuczera, D., Paro de Oliveira, H. H., Fonseca Guimarães, F. de S., de Lima, C., Alves, L., Machado, A. F., Coelho, I., Yamaguchi, A., Donatti, L., Naliwaiko, K., Fernandes, L. C., & Nunes, E. A. (2012). Bax/Bcl-2 Protein Expression Ratio and Leukocyte Function Are Related to Reduction of Walker-256 Tumor Growth After β-Hydroxy-β-Methylbutyrate (HMB) Administration in Wistar Rats. Nutrition and Cancer, 64(2), 286–293. https://doi.org/10.1080/01635581.2012.647229

Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats

Nutrition and Cancer / Nov 01, 2005

Pizato, N., Bonatto, S., Yamazaki, R. K., Aikawa, J., Nogata, C., Mund, R. C., Nunes, E. A., Piconcelli, M., Naliwaiko, K., Curi, R., Calder, P. C., & Fernandes, L. C. (2005). Ratio of n6 to n-3 Fatty Acids in the Diet Affects Tumor Growth and Cachexia in Walker 256 Tumor-Bearing Rats. Nutrition and Cancer, 53(2), 194–201. https://doi.org/10.1207/s15327914nc5302_8

See Full Profile

Dr. Shilpa Patil, Ph.D

Vancouver, British Columbia, Canada
PhD & Postdoc level expertise in Cancer Research
Most Relevant Research Expertise
Oncology
Other Research Expertise (11)
Cancer
epigenetics
development
Cancer Research
Biophysics
And 6 more
About
Dr. Shilpa Patil is a highly experienced cancer researcher with a strong background in Preclinical studies. She received her Ph.D. in Molecular Medicine from the University of Göttingen in 2020, where she focused on developing novel treatments for pancreatic cancer. Prior to that, she completed her MSc in Regenerative Medicine from Manipal University in 2014 and her BSc in Biotechnology from the same institution in 2012. With over 6 years of research experience, Dr. Patil has worked at prestigious institutions such as the University of British Columbia, University of Göttingen and JNCASR. Her expertise lies in the areas of cancer biology, epigenetics, cell and molecular biology, and regenerative medicine. She has published numerous research articles in reputed journals and has presented her work at various international conferences. Dr. Patil is a dedicated and passionate scientist, committed to using her knowledge and skills to contribute to the fight against cancer. She is driven by her curiosity to unravel complex biological processes and her desire to make a positive impact in the field of cancer research. She is also driven to bridge the academia-industry gap.
Most Relevant Publications (3+)

20 total publications

EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6

Cancer Research / Nov 01, 2020

Patil, S., Steuber, B., Kopp, W., Kari, V., Urbach, L., Wang, X., Küffer, S., Bohnenberger, H., Spyropoulou, D., Zhang, Z., Versemann, L., Bösherz, M. S., Brunner, M., Gaedcke, J., Ströbel, P., Zhang, J.-S., Neesse, A., Ellenrieder, V., Singh, S. K., … Hessmann, E. (2020). EZH2 Regulates Pancreatic Cancer Subtype Identity and Tumor Progression via Transcriptional Repression of GATA6. Cancer Research, 80(21), 4620–4632. https://doi.org/10.1158/0008-5472.can-20-0672

TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer

Cancers / Jul 15, 2022

Versemann, L., Patil, S., Steuber, B., Zhang, Z., Kopp, W., Krawczyk, H. E., Kaulfuß, S., Wollnik, B., Ströbel, P., Neesse, A., Singh, S. K., Ellenrieder, V., & Hessmann, E. (2022). TP53-Status-Dependent Oncogenic EZH2 Activity in Pancreatic Cancer. Cancers, 14(14), 3451. https://doi.org/10.3390/cancers14143451

HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells

Cancers / Dec 07, 2021

Ewers, K. M., Patil, S., Kopp, W., Thomale, J., Quilitz, T., Magerhans, A., Wang, X., Hessmann, E., & Dobbelstein, M. (2021). HSP90 Inhibition Synergizes with Cisplatin to Eliminate Basal-like Pancreatic Ductal Adenocarcinoma Cells. Cancers, 13(24), 6163. https://doi.org/10.3390/cancers13246163

See Full Profile

Boris Leibovitch

New York, New York, United States of America
Experienced wet lab and in teaching Molecular Cell biologist, geneticist, cancer biologist in Academia
Most Relevant Research Expertise
Oncology
Other Research Expertise (8)
Cancer Research
Cell Biology
Developmental Biology
Molecular Biology
Hematology
And 3 more
About
I am experienced molecular and cell biologist with deep genetics background who worked many years in USA and Russia on the bench and as teacher. Both types of work had demanded extremely broad knowledge and understanding of developments in the fields. Participation in grant writing, editorial/reviewer work for scientific journals and consulting colleagues on these subjects added a lot to my broad experience as the scientist.
Most Relevant Publications (5+)

22 total publications

Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells

Oncotarget / Aug 19, 2016

Kwon, Y.-J., Leibovitch, B. A., Bansal, N., Pereira, L., Chung, C.-Y., Ariztia, E. V., Zelent, A., Farias, E. F., & Waxman, S. (2016). Targeted interference of SIN3A-TGIF1 function by SID decoy treatment inhibits Wnt signaling and invasion in triple negative breast cancer cells. Oncotarget, 8(51), 88421–88436. https://doi.org/10.18632/oncotarget.11381

Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer

Oncotarget / Jun 07, 2016

Bansal, N., Bosch, A., Leibovitch, B., Pereira, L., Cubedo, E., Yu, J., Pierzchalski, K., Jones, J. W., Fishel, M., Kane, M., Zelent, A., Waxman, S., & Farias, E. (2016). Blocking the PAH2 domain of Sin3A inhibits tumorigenesis and confers retinoid sensitivity in triple negative breast cancer. Oncotarget, 7(28), 43689–43702. https://doi.org/10.18632/oncotarget.9905

Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer

Molecular Cancer Therapeutics / Aug 01, 2015

Kwon, Y.-J., Petrie, K., Leibovitch, B. A., Zeng, L., Mezei, M., Howell, L., Gil, V., Christova, R., Bansal, N., Yang, S., Sharma, R., Ariztia, E. V., Frankum, J., Brough, R., Sbirkov, Y., Ashworth, A., Lord, C. J., Zelent, A., Farias, E., … Waxman, S. (2015). Selective Inhibition of SIN3 Corepressor with Avermectins as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics, 14(8), 1824–1836. https://doi.org/10.1158/1535-7163.mct-14-0980-t

Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer

Oncotarget / Oct 09, 2015

Bansal, N., Petrie, K., Christova, R., Chung, C.-Y., Leibovitch, B. A., Howell, L., Gil, V., Sbirkov, Y., Lee, E., Wexler, J., Ariztia, E. V., Sharma, R., Zhu, J., Bernstein, E., Zhou, M.-M., Zelent, A., Farias, E., & Waxman, S. (2015). Targeting the SIN3A-PF1 interaction inhibits epithelial to mesenchymal transition and maintenance of a stem cell phenotype in triple negative breast cancer. Oncotarget, 6(33), 34087–34105. https://doi.org/10.18632/oncotarget.6048

Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1

Translational Oncology / Feb 01, 2022

Kadamb, R., Leibovitch, B. A., Farias, E. F., Dahiya, N., Suryawanshi, H., Bansal, N., & Waxman, S. (2022). Invasive phenotype in triple negative breast cancer is inhibited by blocking SIN3A–PF1 interaction through KLF9 mediated repression of ITGA6 and ITGB1. Translational Oncology, 16, 101320. https://doi.org/10.1016/j.tranon.2021.101320

See Full Profile

Dr. Michael W. Craige, PhD, MBA

New York
Entrepreneurial Scientist | Research Technology, Informatics & Data Science
Most Relevant Research Expertise
Oncology
Other Research Expertise (5)
Biomedical Informatics
Computational Biology
Neuroinformatics
Bioinformatics
Cancer Research
About
Dr. Michael W. Craige is a research scientist and fellow, leveraging his expertise in biomedical informatics, data science, intellectual property law, and innovation strategy to assess patent, and license new inventions and technologies reported by scientists. He has contributed to publications in high-impact journals, such as Nature Communications and Frontiers in Oncology, and has helped several startups secure their first institutional venture capital funding. His professional journey encompasses a rich blend of roles, including an NSF I-Corps Startup Mentor at Rutgers Office of Innovation Ventures, his recent tenure as a Venture Capital Fellow at SOSV's IndieBio in New York, and training in intellectual property law as a patent agent at Casimir Jones Law Firm. Dr. Craige received his MBA from The Georgia Institute of Technology and his PhD in Biomedical Informatics at Rutgers University where he’s developing computational methods for high-throughput cancer genomic data analysis, including statistical models for elucidating the mechanisms of prostate cancer disease progression and therapeutic response. During his doctoral program, he focused his research on pediatric neurology to understand the underline molecular mechanism of epilepsy in infants, jointly at Emory and Rutgers University. Dr. Craige was the managing director and ex-founder at CiDrep Informatics, a health and scientific-informatics consulting firm, that operated across the US and Canada.
Most Relevant Publications (1+)

3 total publications

Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia

Frontiers in Oncology / Sep 06, 2023

Ramakrishnan, A., Datta, I., Panja, S., Patel, H., Liu, Y., Craige, M. W., Chu, C., Jean-Marie, G., Oladoja, A.-R., Kim, I., & Mitrofanova, A. (2023). Tissue-specific biological aging predicts progression in prostate cancer and acute myeloid leukemia. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1222168

See Full Profile

Dushani L. Palliyaguru, Ph.D.

Baltimore, MD, Maryland, United States of America
Toxicologist | Aging, Nutrition and Metabolism Research Scientist | Systems Biologist
Most Relevant Research Expertise
Oncology
Other Research Expertise (16)
Nutrition
aging
Hematology
Molecular Biology
Food Science
And 11 more
About
·   Highly productive scientist with 13 years of multidisciplinary experience in toxicology, molecular nutrition, and aging/ disease biomarkers ·   Excellent communicator with proven record of advanced writing and presentation skills - manuscripts, conference presentations, and grants ·   Extensive experience in large study design, supervision and coordination, big data analysis, and management of junior scientists
Most Relevant Publications (1+)

20 total publications

Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane

Seminars in Oncology / Feb 01, 2016

Yang, L., Palliyaguru, D. L., & Kensler, T. W. (2016). Frugal chemoprevention: targeting Nrf2 with foods rich in sulforaphane. Seminars in Oncology, 43(1), 146–153. https://doi.org/10.1053/j.seminoncol.2015.09.013

See Full Profile

Example Oncology projects

How can companies collaborate more effectively with researchers, experts, and thought leaders to make progress on Oncology?

Development of Targeted Cancer Therapies

An Oncology expert can collaborate with a pharmaceutical company to develop targeted therapies that specifically attack cancer cells, minimizing side effects and improving patient outcomes.

Identification of Biomarkers for Early Cancer Detection

Working with an Oncology researcher, a diagnostic company can identify biomarkers that indicate the presence of cancer at an early stage, enabling early detection and intervention.

Improving Radiation Therapy Techniques

Collaborating with an Oncology expert, a medical device company can enhance radiation therapy techniques, improving precision and minimizing damage to healthy tissues.

Development of Personalized Treatment Plans

An Oncology researcher can assist a healthcare provider in developing personalized treatment plans for cancer patients, considering individual characteristics and genetic profiles.

Exploring Immunotherapy Approaches

Working with an Oncology expert, a biotech company can explore novel immunotherapy approaches for cancer treatment, harnessing the power of the immune system to fight cancer cells.